-
2023-506524-82-00
5
2015-10-21
Stage IB-IIIA non-small cell lung carcinoma, with a centrally confirme
-
2023-509348-84-00
5
2015-04-27
Chronic Lymphocytic Leukemia
-
2023-505840-20-00
9
2024-08-16
B-Cell Acute Lymphoblastic Leukaemia
-
2023-507220-23-00
5
2024-07-26
Transthyretin Amyloidosis with Cardiomyopathy
-
2023-503823-24-01
3
2024-04-15
Systemic Sclerosis
-
2024-515410-41-00
9
2025-04-01
BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)
-
2024-511350-41-00
9
2025-03-13
Relapsed/Refractory Tumors
-
2024-517340-61-00
5
2024-11-19
Patients after curative intent resection of cholangiocarcinoma
(intrah
-
2024-511363-28-00
5
2024-09-24
hidradenitis suppurativa (HS)
-
2023-510249-79-00
4
2024-09-10
Progressive pulmonary fibrosis (PPF)
-
2024-510863-50-00
4
2024-08-30
Neuroendocrine Neoplasia
Neuroendocrine Tumor
-
2023-508170-28-00
4
2024-08-07
alcohol-related liver disease
-
2024-511628-16-00
4
2024-07-18
Post Covid Syndrome (PCS)
-
2023-510190-34-00
5
2024-06-04
Respiratory Syncytial Virus Infections
-
2022-500918-25-00
5
2024-05-20
Marginal Zone Lymphoma
-
2023-504328-25-00
4
2023-12-27
hidradenitis suppurativa
-
2023-506250-20-00
5
2023-12-11
ulcerative pyoderma gangrenosum
-
2023-503696-15-00
4
2023-11-10
sensorineural hearing loss (SNHL)
-
2024-518778-15-00
5
2023-10-08
post-operative nausea and vomiting in pediatric patients
-
2022-502867-39-00
1
2023-09-29
Advanced solid tumors including non-small cell lung cancer (NSCLC), me
-
2022-501895-25-00
5
2023-09-13
Polymyalgia Rheumatica
-
2022-502821-16-00
4
2023-09-01
Knee Osteoarthritis
-
2023-506824-96-00
4
2023-05-23
The present study will include a population of patients with establish
-
2023-503186-35-00
3
2023-05-03
Hypophosphatasia